272 logo

Mabion DB:272 Stock Report

Last Price

€2.96

Market Cap

€46.0m

7D

-16.1%

1Y

-20.3%

Updated

01 Nov, 2024

Data

Company Financials +

Mabion S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mabion
Historical stock prices
Current Share Pricezł2.96
52 Week Highzł5.57
52 Week Lowzł2.85
Beta0.94
11 Month Change-20.54%
3 Month Change-26.91%
1 Year Change-20.30%
33 Year Change-82.28%
5 Year Changen/a
Change since IPO-78.14%

Recent News & Updates

Recent updates

Shareholder Returns

272DE BiotechsDE Market
7D-16.1%-0.4%-1.8%
1Y-20.3%-14.9%13.2%

Return vs Industry: 272 underperformed the German Biotechs industry which returned -15.2% over the past year.

Return vs Market: 272 underperformed the German Market which returned 16.1% over the past year.

Price Volatility

Is 272's price volatile compared to industry and market?
272 volatility
272 Average Weekly Movement6.5%
Biotechs Industry Average Movement6.4%
Market Average Movement5.0%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 272 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 272's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007244Krzysztof Kaczmarczykwww.mabion.eu

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2.

Mabion S.A. Fundamentals Summary

How do Mabion's earnings and revenue compare to its market cap?
272 fundamental statistics
Market cap€46.02m
Earnings (TTM)€2.35m
Revenue (TTM)€25.40m

19.6x

P/E Ratio

1.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
272 income statement (TTM)
Revenuezł110.79m
Cost of Revenuezł23.94m
Gross Profitzł86.85m
Other Expenseszł76.62m
Earningszł10.24m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Nov 25, 2024

Earnings per share (EPS)0.63
Gross Margin78.39%
Net Profit Margin9.24%
Debt/Equity Ratio0.2%

How did 272 perform over the long term?

See historical performance and comparison